ISRG
Intuitive Surgical, Inc.
$438.00
+1.11% 2026-10-20
Health CareS&P 500
ISRGSPY
1W
+3.8%
1M
+11.4%
3M
+25.1%
6M
-2.9%
YTD
-22.7%
1Y
-4.5%
Live chart
Loading live chart…
Grades vs sector
Momentum11th pct in sectorD-
Momentum
11th pct in sector
12-1 return: -23.9%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Growth78th pct in sectorB+
Growth
78th pct in sector
Revenue growth (YoY): +18.5%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Value11th pct in sectorD-
Value
11th pct in sector
Forward E/P: 2.8% · EBITDA/EV: 2.9%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Profitability80th pct in sectorB+
Profitability
80th pct in sector
Profit margin: +28.4% · Return on equity: +17.4%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15rank 425 of 499 · 12-1 momentum % -15.7
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsWhy is Intuitive Surgical stock sliding today?
Investing.com · 10h ago
Intuitive Surgical (ISRG) files 8-K: results
SEC 8-K · 11h ago
Intuitive Surgical Q3 26 Earnings Conference Call At 4:30 PM ET
Nasdaq · 12h ago
Notable Tuesday Option Activity: LITE, UAL, ISRG
Nasdaq · 14h ago
Stocks Mostly Down Pre-Bell as Earnings Take Center Stage
MT Newswires · 20h ago
Key stats
Market cap$154.7B
P/E (trailing)50.2
P/E (forward)36.1
52-week range328.57 – 603.88
Revenue growth (YoY, latest qtr)+18.5%
Dividend yield0.00%
Analyst consensusBuy (30)
Mean price target$478.53 (+9%)
Valuation and fundamentals
Valuation & fundamentals
Bottom line
Leans expensive
Model read-out from the numbers below, not advice. Score -2 (DCF counts double).
▼DCF (base case)below the price by 36%
▼Forward P/E vs sector36.1x vs median 17.6x
▲Piotroski F-score8/9
▲Altman Z38.0 (safe)
▲Net debt / EBITDA-1.5x
•Analyst target+9% (30 analysts)
Discounted cash flow
Bear
$174
-60%
growth 11% · disc. 12.6% · term. 2.0%
Base
$282
-36%
growth 18% · disc. 11.6% · term. 2.5%
Bull
$419
-4%
growth 22% · disc. 10.6% · term. 3.0%
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Today's price assumes free cash flow grows about 21% a year for 10 years.
Implied
+21%/yr
FCF, last 3 yrs
+27%/yr
FCF, last 5 yrs
+15%/yr
Revenue, last 3 yrs
+17%/yr
Revenue, last 5 yrs
+18%/yr
Same inputs as the DCF above: trailing free cash flow 3.7B, 11.6% discount rate, 2.5% growth after year 10, net cash and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.46 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
P/E (trailing)
pricier
sector median 29.9× · 82nd pct
50.2×pricier
Forward P/E
pricier
sector median 17.6× · 89th pct
36.1×pricier
EV / EBITDA
pricier
sector median 15.8× · 94th pct
43.3×pricier
Price / sales
pricier
sector median 3.1× · 92nd pct
14.0×pricier
Price / book
pricier
sector median 3.5× · 84th pct
8.5×pricier
FCF yield
pricier
sector median 4.1% · 28th pct
2.4%pricier
Forward EPS $12.12 vs trailing $8.72 (+39% expected growth). Forward P/E uses analysts' next-12-month estimate.
Backlog (remaining performance obligations)
RPO
$1.7B
as of 2021-09-30
vs a year ago
+14%
YoY
× TTM revenue
0.16×
coverage
Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).
Quality & financial health
Gross margin
66.7%
Operating margin
31.3%
FCF margin
33.6%
Net margin
28.4%
Return on equity
17.3%
Return on invested capital
22.1%
Net debt / EBITDA
-1.5×
Current ratio
5.0×
Interest cover
–
Cash conversion (OCF/NI)
1.2×
Piotroski F-score 8/9 · last two fiscal years
✓ Positive net income✓ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✓ No share dilution✗ Gross margin improved✓ Asset turnover improved
Altman Z-score 38.0 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Mean target
$479
+9%
Analysts
30
Buy
Range
$324–$685
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $10.1B | $2.9B | $3.0B |
| 2024 | $8.4B | $2.3B | $2.4B |
| 2023 | $7.1B | $1.8B | $1.8B |
| 2022 | $6.2B | $1.3B | $1.5B |
| 2021 | $5.7B | $1.7B | $2.1B |
| 2020 | $4.4B | $1.1B | $1.5B |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +17.4%.
Earnings
Next report: –
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-10-20 | 2.64 | 3.00 | +13.6% |
| 2026-07-16 | 2.50 | 2.80 | +11.9% |
| 2026-04-21 | 2.11 | 2.50 | +18.7% |
| 2026-01-22 | 2.27 | 2.53 | +11.6% |
| 2025-10-21 | 1.99 | 2.40 | +20.7% |
| 2025-07-22 | 1.92 | 2.19 | +14.1% |
| 2025-04-22 | 1.73 | 1.81 | +4.4% |
| 2025-01-23 | 1.79 | 2.21 | +23.7% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $2.9B | +18.5% |
| 2026-03-31 | $2.8B | – |
| 2025-12-31 | $2.9B | – |
| 2025-09-30 | $2.5B | – |
| 2025-06-30 | $2.4B | – |
Analyst actions
BTIG
PT $454
2026-10-12 · main
Buy → BuyPT $454
Barclays
PT $485
2026-10-07 · init
→ OverweightPT $485
BTIG
PT $469
2026-09-08 · reit
Buy → BuyPT $469
Oppenheimer
PT $500
2026-08-12 · up
Perform → OutperformPT $500
HSBC
PT $931
2026-07-30 · down
Buy → HoldPT $931
Raymond James
PT $483
2026-07-17 · main
Outperform → OutperformPT $483
Insider trades
Widman Fredrik
$204.4K
VP Corporate Controller · 2026-09-15
SELL$204.4K
Widman Fredrik
$203.3K
VP Corporate Controller · 2026-09-15
SELL$203.3K
Brosius Mark
$9.1K
EVP & Chief Mfg and Supply Cha · 2026-09-11
SELL$9.1K
Brosius Mark
$8.0K
EVP & Chief Mfg and Supply Cha · 2026-09-10
SELL$8.0K
Brosius Mark
$8.1K
EVP & Chief Mfg and Supply Cha · 2026-09-09
SELL$8.1K
Brosius Mark
$16.6K
EVP & Chief Mfg and Supply Cha · 2026-09-08
SELL$16.6K
Brosius Mark
$28.9K
EVP & Chief Mfg and Supply Cha · 2026-08-21
SELL$28.9K
Brosius Mark
$30.5K
EVP & Chief Mfg and Supply Cha · 2026-08-20
SELL$30.5K
Brosius Mark
$30.4K
EVP & Chief Mfg and Supply Cha · 2026-08-19
SELL$30.4K
Brosius Mark
$30.3K
EVP & Chief Mfg and Supply Cha · 2026-08-18
SELL$30.3K
Brosius Mark
$30.1K
EVP & Chief Mfg and Supply Cha · 2026-08-17
SELL$30.1K
Guthart Gary S
$4.0M
Director · 2026-08-11
SELL$4.0M
Stats refreshed 2026-10-20 17:52:12 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.